Compared to controls (0.32 ± 0.12 g/L), mild NAFLD (0.24 ± 0.16 g/L, p < 0.05) and moderate NAFLD (0.25 ± 0.17 g/L, p < 0.05) patients had significantly lower levels of fetuin-A. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.